ELIAS Animal Health, a medical biotechnology company based in Olathe, Kansas, is dedicated to advancing innovative immunotherapies for the treatment of cancer in pets. Their lead product candidate, the ELIAS cancer immunotherapy (ECI®), is an autologous prescription product currently available to veterinarians as an experimental treatment. Although efficacy and safety have not yet been established, this novel therapeutic approach holds great promise for improving clinical outcomes and revolutionizing cancer treatment in animals.

At ELIAS Animal Health, their mission is to enhance cancer treatment outcomes in veterinary patients through the development of cutting-edge therapies. They are driven by a passion for the well-being of pets and their healthcare, demonstrating compassion towards pet owners and veterinarians. The company prioritizes data-driven decisions and focuses on evidence-based scientific claims, ensuring the highest standard of care.

For veterinarians and pet owners seeking information about ELIAS Animal Health's immunotherapy, they provide comprehensive resources, including clinical trial results, veterinary and pet owner information, success stories, and frequently asked questions. With a commitment to excellence, ELIAS Animal Health aims to transform the field of veterinary oncology and make a meaningful difference in the lives of pets and their owners